These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7717370)

  • 1. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid.
    Letendre L; Levitt R; Pierre RV; Schroeder G; Krook JA; Mailliard JE; Morton RF; Tschetter LK
    Am J Hematol; 1995 Apr; 48(4):233-6. PubMed ID: 7717370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
    Guan M; Chen SC; Li RS; Ge CW; Zhu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone.
    Sadek I; Zayed E; Hayne O; Fernandez L
    Am J Hematol; 2000 Aug; 64(4):306-10. PubMed ID: 10911385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 13-cis-Retinoic acid treatment in patients with myelodysplastic syndrome.
    Leoni F; Ciolli S; Longo G; Messori A; Ferrini PR
    Acta Haematol; 1988; 80(1):8-12. PubMed ID: 3135696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of myelodysplastic syndromes.
    Buzaid AC; Garewal HS; Greenberg BR
    Am J Med; 1986 Jun; 80(6):1149-57. PubMed ID: 3524212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
    Hofmann WK; Kell WJ; Fenaux P; Castaigne S; Ganser A; Chomienne C; Burnett R; Kowal C; Hoelzer D; Burnett AK
    Leukemia; 2000 Sep; 14(9):1583-8. PubMed ID: 10995004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
    Greenberg BR; Durie BG; Barnett TC; Meyskens FL
    Cancer Treat Rep; 1985 Dec; 69(12):1369-74. PubMed ID: 3865701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
    Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
    Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
    Feng FE; Feng R; Wang M; Zhang JM; Jiang H; Jiang Q; Lu J; Liu H; Peng J; Hou M; Shen JL; Wang JW; Xu LP; Liu KY; Huang XJ; Zhang XH
    Lancet Haematol; 2017 Oct; 4(10):e487-e496. PubMed ID: 28917657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danazol in the treatment of myelodysplastic syndromes.
    Buzaid AC; Garewal HS; Lippman SM; Durie BG; Katakkar SB; Greenberg BR
    Eur J Haematol; 1987 Oct; 39(4):346-8. PubMed ID: 3319676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
    Kurzrock R; Estey E; Talpaz M
    J Clin Oncol; 1993 Aug; 11(8):1489-95. PubMed ID: 8336187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Danazol as First-Line Therapy for Myelodysplastic Syndrome.
    Colunga-Pedraza PR; Colunga-Pedraza JE; Garza-Ledezma MA; Jaime-Pérez JC; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Rendón-Ramírez EJ; López-García YK; Lozano-Morales RE; Gómez-De León A; Sotomayor-Duque G; Gómez-Almaguer D
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e109-e113. PubMed ID: 29268959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of 76 patients with myelodysplastic syndromes treated with danazol.
    Chabannon C; Molina L; Pégourié-Bandelier B; Bost M; Léger J; Hollard D
    Cancer; 1994 Jun; 73(12):3073-80. PubMed ID: 8200005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of danazol in myelodysplastic syndromes.
    Marini B; Bassan R; Barbui T
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1481-9. PubMed ID: 3181270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
    Nair R; Nair CN; Advani SH
    Leuk Lymphoma; 1998 Mar; 29(1-2):187-92. PubMed ID: 9638988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.
    Koeffler HP; Heitjan D; Mertelsmann R; Kolitz JE; Schulman P; Itri L; Gunter P; Besa E
    Blood; 1988 Mar; 71(3):703-8. PubMed ID: 3278754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of danazol vs. placebo in myelodysplastic syndromes.
    Avilés A; Rubio ME; Gómez J; Medina ML; González-Llaven J
    Arch Invest Med (Mex); 1989; 20(2):183-8. PubMed ID: 2690768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation therapy of myelodysplastic syndromes with retinoic acid.
    Ohno R
    Leuk Lymphoma; 1994 Aug; 14(5-6):401-9. PubMed ID: 7812199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.